{"id":"NCT01134263","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia","officialTitle":"Lot-to-Lot Consistency and Bridging Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-10-05","primaryCompletion":"2012-11","completion":"2013-02","firstPosted":"2010-05-31","resultsPosted":"2019-07-24","lastUpdate":"2019-07-24"},"enrollment":715,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Dengue Fever","Dengue Hemorrhagic Fever"],"interventions":[{"type":"BIOLOGICAL","name":"Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus","otherNames":["CYD Dengue vaccine"]},{"type":"BIOLOGICAL","name":"Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus","otherNames":["CYD Dengue vaccine"]},{"type":"BIOLOGICAL","name":"Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus","otherNames":["CYD Dengue vaccine"]},{"type":"BIOLOGICAL","name":"Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus","otherNames":["CYD Dengue vaccine"]},{"type":"BIOLOGICAL","name":"Placebo: NaCl 0.9%","otherNames":["NaCl"]}],"arms":[{"label":"CYD Dengue Vaccine Phase III Lot 1","type":"EXPERIMENTAL"},{"label":"CYD Dengue vaccine - Phase III Lot 2","type":"EXPERIMENTAL"},{"label":"CYD Dengue vaccine - Phase III Lot 3","type":"EXPERIMENTAL"},{"label":"CYD Dengue vaccine - Phase II Lot","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to demonstrate that different CYD dengue vaccine lots manufactured using the same method and in the same location but at different times produce an equivalent immunological response after 3 doses.\n\nPrimary Objective\n\n* To demonstrate that three different Phase III lots of CYD dengue vaccine induce an equivalent immune response in terms of post-Dose 3 geometric mean titers (GMTs) against the four parental serotypes.\n\nSecondary Objectives:\n\n* To demonstrate that data from one Phase II lot and pooled data from Phase III lots of CYD dengue vaccine show an equivalent immune response in terms of post-Dose 3 GMTs against the four parental serotypes.\n* To describe the safety of the CYD dengue vaccine in all participants after each dose.","primaryOutcome":{"measure":"Post-Dose 3 Geometric Mean Titers (GMTs) of Antibodies Against Each of the Four Dengue Virus Serotypes Following Vaccination With Phase III Lots of CYD Dengue Vaccine","timeFrame":"28 days post-injection 3","effectByArm":[{"arm":"CYD Dengue Vaccine Phase III Lot 1","deltaMin":20.6,"sd":null},{"arm":"CYD Dengue Vaccine Phase III Lot 2","deltaMin":18.1,"sd":null},{"arm":"CYD Dengue Vaccine Phase III Lot 3","deltaMin":17.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG002","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":14},"locations":{"siteCount":8,"countries":["Australia"]},"refs":{"pmids":["26279339","28968794"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":163},"commonTop":["Headache","Malaise","Myalgia","Injection Site Pain","Asthenia"]}}